COMPANY INFO
The actual company name is Loyal. It was founded in 2019 by Celine Halioua. Loyal has approximately 196 employees and is headquartered in San Francisco, CA. The company operates in the Other Consumer Non-Durables industry and focuses on developing veterinary drugs intended to improve dogs' health span and lifespan. Loyal's drugs aim to delay the onset of age-related diseases such as cancer, heart diseases, and metabolic diseases, enabling dogs to live healthier, longer lives. Their website is associated with loyalfordogs.com. (PitchBook, Tracxn, Aspen Ideas Festival)
Loyal is a biotechnology research company founded in 2019 by Celine Halioua and headquartered in San Francisco, CA. The company has around 196 employees and operates within the Other Consumer Non-Durables industry. Loyal is focused on developing veterinary drugs that improve the health span and lifespan of dogs, aiming to delay the onset of age-related diseases such as cancer, heart disease, and metabolic disorders. Their innovative approach targets extending the healthy years that dogs enjoy, ultimately enabling pets to live longer, healthier lives.
Loyal has been proactive about securing capital to fuel its pioneering work in canine longevity. The company has raised a total of $150 million over six funding rounds, leveraging partnerships with leading venture capital firms and strategic investors. This strong fundraising history reflects Loyal’s commitment to research and development, product launches, and scaling operations to bring longevity solutions for pets to market. The company’s funding strategy demonstrates a blend of significant venture capital support and focused operational expansion as they target the first FDA-approved lifespan extension drug for dogs.
This round was used to expand Loyal’s operations and accelerate research & development initiatives, supporting long-term growth and technology advancement.
The Series B funding enabled Loyal to continue developing the first FDA-approved drug aimed at extending canine lifespan and laying the groundwork for the product launch planned for early 2025.
Loyal’s Series A round fueled product refinement along with initial clinical trials to validate the safety and efficacy of their canine longevity treatments.
Seed funding helped launch the company, supporting early development work on drug candidates designed to delay age-related canine diseases.
A prominent venture capital firm supporting mission-driven companies, Collaborative Fund participated in multiple rounds and has played a strategic role in backing Loyal’s vision of transforming canine longevity. Their involvement underscores the market and societal need Loyal addresses.
Valor Equity Partners invested in Loyal’s Series B-2 round, contributing expertise in scaling innovative technology and operational excellence as Loyal grows.
Bridge Bank is a financial partner that provides tailored banking solutions and growth capital, helping Loyal maintain strong financial health and flexibility during pivotal development phases.
As a lead investor in the Series B round, Bain Capital Ventures has been instrumental in supporting Loyal’s product development and commercialization efforts, bringing deep expertise in scaling high-growth biotechnology ventures.
An early investor in Loyal’s Seed and Series A rounds, Khosla Ventures provided foundational funding and guidance, enabling Loyal to advance its scientific research and initial product pipelines.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Loyal funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.